Clinical Trial Update: Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating secukinumab for active peripheral spondyloarthritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Peripheral Spondyloarthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Active Peripheral Spondyloarthritis (pSpA) | Phase 3 | Status: WITHDRAWN